Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

NCT06176235 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Trial withdrawn due to substantial protocol amendments invalidating the original design. With no participants enrolled, this aligns with WHO-ICTRP guidelines. Recruitment has ceased, and the revised protocol has been re-registered as NCT07065968.

Conditions

Interventions

Sponsor

Peking University People's Hospital

Collaborators